Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST-021p in Advanced Solid Tumors
NCT04864418Phase 1Completed
- Sponsor
- Aston Sci
- Start
- Jun 2021
- Primary completion
- Nov 2023
- Modality
- Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of AST-021p in solid tumor (4 arms), sponsored by Aston Sci. Primary endpoint: Treatment-related adverse events at 20 weeks. Started Jun 2021; status: completed.
02
Drugs
AST-021p
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04864418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864418.